Qilu Pharmaceutical Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS75
PHASE 3 / 2-344
RECRUITING28
READOUTS ≤12 MONTHS34
READOUT SLIPPED >6 MO9%
Delay Index: of 33 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Qilu Pharmaceutical Co., Ltd. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| QLF31907 NCT06394713 |
P1/2 | Not yet recruiting | Advanced Malignant Neoplasm | 60 | 2025-06-15 |
| QLC7401 NCT06750341 |
P2 | Not yet recruiting | Primary Hypercholesterolemia or Mixed Hyperlipidemia | 156 | 2026-06 |
| QLM3004 Concentration 1 NCT06151587 |
P3 | Recruiting | Myopia | 735 | 2026-06 |
| QLS31905 NCT06446388 |
P2 | Not yet recruiting | Advanced Solid Tumor | 360 | 2026-06-30 |
| MHB088C for Injection NCT07102004 |
P1/2 | Recruiting | Advanced/Metastatic Solid Tumors | 515 | 2026-07 |
| GM1 NCT06994507 |
P3 | Recruiting | Chemotherapy-induced Peripheral Neuropathy (CIPN) | 352 | 2026-09 |
| QLC1101+QL1203 NCT06949761 |
P1/2 | Not yet recruiting | Solid Tumor | 240 | 2026-09 |
| QLC5508 NCT07256782 |
P1/2 | Recruiting | Advanced Solid Tumor | 444 | 2026-10 |
| QLS31905 for Injection NCT07151872 |
P2 | Not yet recruiting | CLDN18.2-positive Advanced Biliary Tract Cancer | 120 | 2026-10 |
| 3-6mg QLM1016 NCT06799559 |
P3 | Active, not recruiting | Schizophrenia | 402 | 2026-10-23 (+4 mo) |
| Relugolix NCT06671548 |
P3 | Recruiting | Heavy Menstrual Bleeding; Uterine Fibroids | 120 | 2026-11-12 |
| Meropenem and Pralurbactam NCT07089186 |
P3 | Recruiting | Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP) | 80 | 2026-12 |
| QL2107 NCT06754644 |
P3 | Recruiting | NSCLC | 808 | 2026-12 |
| QL1207H injection NCT07489586 |
P3 | Not yet recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 356 | 2026-12 |
| QLG1091 NCT07487103 |
P3 | Not yet recruiting | Type 2 Diabetes | 478 | 2026-12 |
| QLC5508 NCT07198633 |
P1/2 | Recruiting | Advanced Prostate Cancer | 212 | 2026-12 |
| Dose 1 of QLS1410 NCT07489612 |
P2 | Enrolling by invitation | Hypertension (HTN) | 260 | 2026-12 |
| QLS31905 for Injection NCT06942767 |
P2 | Not yet recruiting | Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | 100 | 2026-12 |
| QL2107 NCT07162883 |
P3 | Active, not recruiting | Carcinoma, Non-Small-Cell Lung | 146 | 2026-12-31 |
| QL1206 NCT07062978 |
P3 | Recruiting | Postmenopausal Women With Osteoporosis at High Risk of Fracture | 278 | 2027-01 |
| QLC1401 NCT07173556 |
P1/2 | Not yet recruiting | Advanced Breast Cancer | 96 | 2027-02 |
| 1.5% QLM3003 ointment NCT06880276 |
P3 | Recruiting | Atopic Dermatitis | 360 | 2027-03 |
| QLS5132; Bevacizumab NCT07453394 |
P1/2 | Not yet recruiting | Gastric Cancer (GC); Non-small Cell Lung Cancer (NSCLC) | 626 | 2027-04 |
| QLS1410 NCT07550465 |
P2 | Not yet recruiting | Primary Aldosteronism | 60 | 2027-04 |
| QL0911 NCT06456528 |
P2/3 | Recruiting | Cancer Treatment-Induced Thrombocytopenia | 235 | 2027-04-30 (+10 mo) |
| Daprodustat NCT07300111 |
P3 | Not yet recruiting | Anaemia | 100 | 2027-05 |
| MHB088C for Injection NCT06954246 |
P3 | Recruiting | Small Cell Lung Cancer Extensive Stage | 450 | 2027-05 |
| QLG2128 NCT06898060 |
P3 | Not yet recruiting | Postmenopausal Women With Osteoporosis | 282 | 2027-05 |
| QL2108 injection NCT06884891 |
P3 | Not yet recruiting | Atopic Dermatitis | 520 | 2027-05 |
| Meropenem and Pralurbactam NCT06633718 |
P3 | Not yet recruiting | Intra-abdominal Infections | 786 | 2027-05-30 |
| ESG401 NCT06732323 |
P3 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 504 | 2027-06 |
| QLC5513 IV infusion NCT07272590 |
P1/2 | Not yet recruiting | Metastatic Solid Tumors | 290 | 2027-06 |
| QL2401 25 mg NCT07620366 |
P2 | Not yet recruiting | Metabolic Dysfunction-associated Steatohepatitis (MASH) | 132 | 2027-06 |
| Voclosporin(QL1074) NCT06406205 |
P3 | Recruiting | Lupus Nephritis | 270 | 2027-06 |
| QLS12010 NCT07417917 |
P2 | Not yet recruiting | Adults With Moderate-to-severe Hidradenitis Suppurativa | 102 | 2027-06-01 |
| Albipagrastim alf NCT07724756 |
P2 | Recruiting | Pediatric Malignant Solid Tumor; Febrile Neutropenia (FN) | 18 | 2027-06-26 |
| ESG401 NCT06383767 |
P3 | Recruiting | Metastatic Breast Cancer | 378 | 2027-06-30 (+11 mo) |
| QLS5133 NCT07061639 |
P1/2 | Not yet recruiting | Advanced Solid Tumors | 212 | 2027-07 |
| QL1706 injection NCT05487391 |
P3 | Recruiting | Carcinoma, Non-Small-Cell Lung | 632 | 2027-08-31 |
| QLS12010 NCT07344051 |
P2 | Not yet recruiting | Moderate-to-severe Atopic Dermatitis | 160 | 2027-09 |
| QL1706 NCT05976568 |
P2/3 | Not yet recruiting | Hepatocellular Carcinoma | 668 | 2027-09-01 |
| QLH12016 NCT07104110 |
P1/2 | Not yet recruiting | Prostatic Neoplasms | 50 | 2027-10 |
| QLC7401 NCT07444086 |
P3 | Not yet recruiting | Primary Hypercholesterolemia or Mixed Hyperlipidemia | 510 | 2027-10-07 |
| QLS32015 NCT07018050 |
P2 | Recruiting | Relapsed or Refractory Multiple Myeloma | 160 | 2027-11 |
| QLS5133; Lenvatinib mesylate NCT07933419 |
P1/2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma; Ovarian Cancer | 558 | 2027-11-15 |
| QLP2117 NCT06911827 |
P1/2 | Recruiting | Advanced Solid Tumor | 149 | 2027-12 |
| QLC7401 NCT07441317 |
P3 | Not yet recruiting | Primary Hypercholesterolemia or Mixed Hyperlipidemia | 780 | 2027-12 |
| Dose 1 of QLS1410 NCT07927556 |
P2 | Not yet recruiting | Uncontrolled Hypertension | 260 | 2027-12 |
| QL2109 NCT06742138 |
P3 | Not yet recruiting | Multiple Myeloma | 284 | 2027-12 |
| QLS32015 NCT07138209 |
P3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 228 | 2027-12 |
| QL0911 NCT07455006 |
P3 | Not yet recruiting | Thrombocytopenia, Immune | 60 | 2027-12-10 |
| QL2106 injection NCT07511647 |
P3 | Active, not recruiting | Plaque Psoriasis | 318 | 2027-12-30 |
| Iparomlimab and Tuvonralimab (QL1706) NCT06789796 |
P3 | Not yet recruiting | Small-cell Lung Cancer | 636 | 2028-03 |
| GM1 NCT07585565 |
P2 | Not yet recruiting | Parkinson's Disease | 276 | 2028-03 |
| QLS12010 NCT07377773 |
P2 | Not yet recruiting | Rheumatoid Arthritis (RA) | 180 | 2028-03-05 |
| QLC7401 Injection NCT07450378 |
P3 | Not yet recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 120 | 2028-04 |
| QLS4131 NCT07560449 |
P2 | Not yet recruiting | Malignant Plasma Cell Neoplasms | 162 | 2028-06 |
| Meropenem and Pralurbactam NCT07327619 |
P3 | Recruiting | Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia | 420 | 2028-06 |
| QLC5508 NCT07463573 |
P3 | Recruiting | Esophageal Squamous Cell Carcinoma (ESCC) | 466 | 2028-06-05 |
| QLC5508 NCT07632690 |
P3 | Not yet recruiting | Prostate Cancer | 700 | 2028-06-20 |
| QL1706 NCT07025239 |
P3 | Not yet recruiting | Metastatic Colorectal Cancer | 430 | 2028-07 |
| QLS7305 Injection NCT07730632 |
P2 | Not yet recruiting | IgAN - IgA Nephropathy; Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) | 60 | 2028-08-10 |
| QLS31905 NCT07716449 |
P3 | Recruiting | Gastric or Gastroesophageal Junction Adenocarcinoma | 560 | 2028-09 |
| QLS2319 NCT07735104 |
P1/2 | Recruiting | Cancer Cachexia; Cancer Cachexia Syndrome | 88 | 2028-10-30 |
| QLS1304 tablet+Fulvestrant or QLC1401 NCT07235176 |
P1/2 | Recruiting | Advanced ER+/HER2- Breast Cancer | 300 | 2028-11-02 |
| QLS31905 NCT07079228 |
P3 | Recruiting | Pancreatic Cancer | 602 | 2028-12 |
| tezepelumab (Arm1&Arm2) NCT07302516 |
P3 | Not yet recruiting | Asthma | 636 | 2028-12 |
| QLC5508 NCT07802821 |
P3 | Recruiting | Extensive-stage Small Cell Lung Cancer | 556 | 2029-03-15 |
| Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen) NCT07894211 |
P3 | Not yet recruiting | Extrapulmonary Neuroendocrine Carcinoma | 270 | 2029-03-26 |
| QL1706 NCT05690945 |
P3 | Active, not recruiting | Lung Cancer | 606 | 2029-06 (+47 mo) |
| Romiplostim N01 NCT07345000 |
P3 | Not yet recruiting | Treatment-naïve Severe Aplastic Anemia | 210 | 2029-10 |
| QLS5132 NCT07926048 |
P3 | Not yet recruiting | Epithelial Ovarian Cancer; Fallopian Tube Cancer | 420 | 2029-12 |
| QLS4131 NCT07933432 |
P3 | Not yet recruiting | Relapsed or Refractory Multiple Myeloma | 300 | 2029-12-14 |
| Iparomlimab and Tuvonralimab (QL1706)Injection NCT06852456 |
P2 | Not yet recruiting | Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | 30 | 2030-12 |
| QL1706 NCT06686576 |
P3 | Recruiting | Colon Cancer | 363 | 2030-12 |